Craft

uniQure

Stock Price

$6.4

2024-10-29

Market Capitalization

$312.6 M

2024-10-29

Revenue

$16.1 M

FY, 2025

uniQure Summary

Company Summary

Overview
uniQure is a company that provides gene therapy solutions. It develops a platform focused on liver-directed and central nervous system (CNS) disorders. The platform allows the development, manufacturing, and clinical testing of gene therapies for multiple diseases using the same set of components, including capsids, promoters, and manufacturing methods.
Type
Public
Status
Active
Founded
1998
HQ
Amsterdam, NL | view all locations
Website
https://www.uniqure.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Matt Kapusta

    Matt Kapusta, Chief Executive Officer and Executive Board Member

  • Walid Abi-Saab

    Walid Abi-Saab, Chief Medical Officer

  • Jeannette Potts

    Jeannette Potts, Chief Legal and Compliance Officer

  • Christian Klemt

    Christian Klemt, Chief Financial Officer

Operating MetricsView all

Facilities

5
25.0%

FY, 2022

Facility Space, sq. ft.

253.1K

FY, 2022

Facilities Leased

5
25.0%

FY, 2022

LocationsView all

5 locations detected

  • Amsterdam, NH HQ

    Netherlands

    Paasheuvelweg 25a

  • Lexington, MA

    United States

    113 Hartwell Ave

  • Lexington, MA

    United States

    1 Hartwell Pl

  • Lexington, MA

    United States

    20 Maguire Rd

  • Allschwil, BL

    Switzerland

    Hegenheimermattweg 167A

uniQure Financials

Summary Financials

Revenue (Q1, 2026)
$3.6M
Gross profit (Q1, 2026)
$3.3M
Net income (Q1, 2026)
($53.5M)
Cash (Q1, 2026)
$140.0M
EBIT (Q1, 2026)
($45.7M)
Enterprise value
$236.0M

Footer menu